Christopher Frankenfield
Fortuna: 16 116 $ al 31/07/2026
Fortuna: 16 116 $ al 31/07/2026
Mr. Christopher Frankenfield is a Chief Operating & Financial Officer at Xilio Therapeutics, Inc. Mr. Frankenfield was previously employed as a Vice President-Corporate & Legal Affairs by Blueprint Medicines Corp.
and a Senior Associate by Wilmer Cutler Pickering Hale & Dorr LLP.
He received his undergraduate degree from The College of William & Mary and a graduate degree from the University of Virginia School of Law.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
XILIO THERAPEUTICS INC 0,03 % | 02/01/2026 | 1.769 ( 0,03 % ) | 16 116 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Director Financiero/CFO | 08/08/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Consejero General | 01/03/2021 |
Wilmer Cutler Pickering Hale & Dorr LLP
Wilmer Cutler Pickering Hale & Dorr LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Wilmer Cutler Pickering Hale & Dorr LLP
Wilmer Cutler Pickering Hale & Dorr LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
The College of William & Mary
The College of William & Mary Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blueprint Medicines Corp.
Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
University of Virginia School of Law
University of Virginia School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.